EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
Metabolic Disorders
-
-
EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
On September 30, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
Regeneron Pharmaceuticals’ Phase II trial of its muscle-preservation drug for patients using glucagon-like peptide-1 receptor agonists (GLP-1RAs) has met its…
-
EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks
On 30 September, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan,…
-
EASD 2026: Semaglutide shows promise in treating obesity-related heart failure
At the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, research was presented that showed encouraging results…
-
Zealand dips on Boehringer-paired obesity drug’s Phase III result
Zealand Pharma’s share price fell by 12% after its partnered obesity hopeful, survodutide, failed to impress in a Phase III…
-
EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data from the OCTANE study…
-
EASD 2026: Semaglutide dose escalation shows lower CV risk vs tirzepatide in diabetes
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data compared cardiovascular outcomes with…
-
Roche’s acquired GLP-1/GIP normalises blood sugar in Phase II trial
Roche’s acquired GLP-1/GIP receptor agonist, enicepatide, normalised blood sugar and reduced weight in patients with type 2 diabetes and overweight…
-
Amylyx’s $35m-acquired PBH drug meets endpoints in Phase III trial
Amylyx Pharmaceuticals’ $35m bet on Eiger BioPharmaceuticals’ glucagon-like peptide-1 (GLP-1) receptor antagonist for post-bariatric hypoglycaemia (PBH) has paid off after…
